Pending FDA regs
According to FDA regulatory agenda published in Oct. 22 Federal Register, final NDA rewrite regs are scheduled for publication in December 1984; IND rewrite is scheduled for March 1985. Also scheduled for December publication is proposal for sulfiting agents in drugs and OTC exclusivity policy
You may also be interested in...
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.